CIK 0001370053
- Non-accelerated filer
- Smaller reporting company
ANAPTYSBIO, INC
Sign in to watch- Ticker
- ANAB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203828755
- Phone
- +1 858-362-6295
- Business address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
- Former names
- ANAPTYSBIO INC, ANAPTYS BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $249,372
- in 1 filing, $249K under 10b5-1 plans
Net −$249,372. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 67 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-03 | LOUMEAU ERIC J Chief Legal Officer | Grant or award · Stock Option (right to buy) | +79,780 | 79,780 | ||
| 2024-01-03 | LOUMEAU ERIC J Chief Legal Officer | Grant or award · Restricted Stock Unit | +29,150 | 29,150 | ||
| 2024-01-03 | MULROY DENNIS Chief Financial Officer | Grant or award · Stock Option (right to buy) | +90,780 | 90,780 | ||
| 2024-01-03 | MULROY DENNIS Chief Financial Officer | Grant or award · Restricted Stock Unit | +33,170 | 33,170 | ||
| 2024-01-03 | FENTON DENNIS M Director | Grant or award · Stock Option (right to buy) | +16,510 | 16,510 | ||
| 2024-01-03 | FENTON DENNIS M Director | Grant or award · Restricted Stock Unit | +6,030 | 6,030 | ||
| 2024-01-03 | Faga Daniel CEO | Grant or award · Stock Option (right to buy) | +379,620 | 379,620 | ||
| 2024-01-03 | Faga Daniel CEO | Grant or award · Restricted Stock Unit | +138,710 | 138,710 | ||
| 2024-01-03 | Ware J. Anthony Director | Grant or award · Stock Option (right to buy) | +16,510 | 16,510 | ||
| 2024-01-03 | Ware J. Anthony Director | Grant or award · Restricted Stock Unit | +6,030 | 6,030 | ||
| 2023-11-22 | LOUMEAU ERIC J Chief Legal Officer | Sale | −882 | $14.19 | $13K | 0 |
| 2023-09-18 | LOUMEAU ERIC J Chief Legal Officer | Sale | −3,895 | $19.32 | $75K | 882 |
| 2023-09-18 | MULROY DENNIS Chief Financial Officer | Sale | −3,895 | $19.32 | $75K | 964 |
| 2023-09-15 | Orwin John A Director | Grant or award · Stock Option (right to buy) | +3,311 | 3,311 | ||
| 2023-09-15 | Orwin John A Director | Grant or award · Stock Option (right to buy) | +10,600 | 10,600 | ||
| 2023-09-15 | Orwin John A Director | Grant or award · Restricted Stock Unit | +2,035 | 2,035 | ||
| 2023-09-15 | Orwin John A Director | Grant or award · Restricted Stock Unit | +3,900 | 3,900 | ||
| 2023-09-14 | Lizzul Paul F. Chief Medical Officer | Exercise or conversion | +6,000 | 8,632 | ||
| 2023-09-14 | Lizzul Paul F. Chief Medical Officer | Sale | −2,105 | $19.48 | $41K | 6,527 |
| 2023-09-14 | Lizzul Paul F. Chief Medical Officer | Exercise or conversion · Restricted Stock Unit | −6,000 | 6,000 |
Page 19 of 27 · 522 trades